Diagnoses of myeloproliferative disorder is based on molecular marker. Chronic Myeloid Leukemia and Myeloproliferative neoplasms were considered mutually exclusive and co-existence of BCR/ABL1 and JAK2 mutation is a rare phenomenon.
Case report
Here, we present two cases of co-existence of BCR-ABL and JAK2V617F positivity. We characterize the course of the disease, mainly the minimal residual disease.
Management and outcome: The two cases was initially managed as Chronic Myeloid Leukemia and treated by TKI inhibitors. The first one was diagnosed in 2010. He started the first line of TKI, and then switched to second line without obtaining a major molecular response. Hence he was tested for JAK2V617F mutation and positivity was diagnosed. The second patient showed Chronic Myeloid Leukemia phenotype with coexistence of BCR/ABL1 and JAK2 mutation at diagnosis. Molecular monitoring reveals a high BCR-ABL1 transcript level (20%) at the last follow-up (12 months).
Discussion
Ours results highlight that JAK2V617F/BCR-ABL double positivity may be a potential marker of resistance in Chronic Myeloid Leukemia and clonal molecular analysis is mandatory to elucidate the mechanism. Moreover, the combination of JAK and TKI inhibitors might be effective and potentially be guided by molecular monitoring of minimal residual disease.
BarbuiTThieleJGisslingerH, et al.
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J2018;
8: 15.
2.
KannimSThongnoppakhunWAuewarakulCU.Two-round allele specific-polymerase chain reaction: a simple and highly sensitive method for JAK2V617F mutation detection. Clin Chim Acta2009;
401: 148–151.
3.
KramerAReiterAKruthJ, et al.
JAK2-V617F mutation in a patient with philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol2007;
8: 658–660.
4.
PahoreZAShamsiTSTajM, et al.
JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression. J Coll Physicians Surg Pak2011;
21: 472–475.
5.
CampiottiLAppioLSolbiatiF, et al.
JAK2-V617F mutation and philadelphia positive chronic myeloid leukemia. Leuk Res2009;
33: e212–e213.
6.
LewandowskiKGniotMWojtaszewskaM, et al.
Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Int J Lab Hematol2018;
40: 366–371.
7.
DarlingHSKumarRKapoorR, et al.
BCR-ABL and JAK2V617F mutation co-existence, rare or just unexplored. Indian J Hematol Blood Transfus2017;
33: 633–635.
8.
PagnanoKBBDelamainMTMagnusMM, et al.
Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up. Oncol Lett2016;
12: 485–487.
9.
PastoreFSchneiderSChristO, et al.
Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F. Exp Hematol Oncol2013;
2: 24.
10.
HassanADogaraLGBabadokoAA, et al.
Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm. Niger Med J2015;
56: 74–76.
11.
HusseinKBockOSeegersA, et al.
Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood2007;
109: 4106–4107.
12.
XuWChenBTongX.Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation. Int J Hematol2014;
99: 87–90.
13.
De RoeckLMichauxLDebackereK, et al.
Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. Hematology2018;
23: 785–792.
14.
BodduPMasarovaLVerstovsekS, et al.
Patient characteristics and outcomes in adolescents and young adults with classical philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol2018;
97: 109–121.
15.
Martin-CabreraPHaferlachCKernW, et al.
BCR-ABL1-positive andJAK2V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance. Br J Haematol2017;
176: 135–139.
16.
MirzaIFrantzCClarkeG, et al.
Transformation of polycythemia vera to chronic myelogenous leukemia. Arch Pathol Lab Med2007;
131: 1719–1724.
17.
InamiMInokuchiKOkabeM, et al.
Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia2007;
21: 1103–1104.
18.
BornhäuserMMohrBOelschlaegelU, et al.
Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia2007;
21: 1824–1826.
19.
CambierNRennevilleACazaentreT, et al.
JAK2V617F-positive polycythemia vera and philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia2008;
22: 1454–1455.
20.
ScottLMCampbellPJBaxterEJ, et al.
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood2005;
106: 2920–2921.
21.
ParkSHChiH-SChoY-U, et al.
Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment. Ann Lab Med2013;
33: 229–232.
22.
LeeYJMoonJHShinHC, et al.
Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate. Int J Hematol2013;
97: 804–807.
23.
De ConchonMRMCostaJLNovaesMMY, et al.
Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol2008;
88: 243–245.
24.
PardiniSFozzaCContiniS, et al.
A case of coexistence between JAK2V617F and BCR/ABL. Eur J Haematol2008;
81: 75–76.
25.
KimY-KShinM-GKimH-R, et al.
Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders. Leuk Res2008;
32: 993–995.
26.
BodduPChiharaDMasarovaL, et al.
The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol2018;
97: 2071–2080.
27.
FavaCCambrinGRFerreroD, et al.
Coexistence of a JAK2 mutated clone may cause hematologic resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma2009;
9: E41.
28.
TefferiA, Levitt R, Lasho TLet al.
Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. Eur J Haematol2010;
85: 86–87.
29.
HusseinKBockOTheophileK, et al.
Chronic myeloproliferative diseases with concurrent BCR–ABL junction and JAK2V617F mutation. Leukemia2008;
22: 1059–1062.
30.
VéronèseLTchirkovARichard-PebrelC, et al.
A thrombocytosis occurring in philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2V617F myeloproliferative neoplasm. Leuk Res2010;
34: e94–e96.
31.
CaocciGAtzeniSOrrùN, et al.
Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190BCR–ABL oncoprotein and JAK2V617F mutation. Leuk Res2010;
34: e27–e29.
32.
PastoreFSchneiderSChristO, et al.
Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F. Exp Hematol Oncol2013;
2: 24.
33.
MaerkiJKatavaGSiegelD, et al.
Unusual case of simultaneous presentation of plasma cell myeloma, chronic myelogenous leukemia, and a Jak2 positive myeloproliferative disorder. Case Rep Hematol2014;
2014: 738428.
34.
BaderGDreilingB.Concurrent JAK2-Positive myeloproliferative disorder and chronic myelogenous leukemia: a novel entity? A case report with review of the literature. J Investig Med High Impact Case Rep2019;
7: 232470961983232.
35.
ShiX-BJiangJ-FJinF-X, et al.
Coexistence of breakpoint cluster region-Abelson1 rearrangement and janus kinase 2 V617F mutation in chronic myeloid leukemia: a case report. World J Clin Cases2019;
7: 1087–1092.
